583 related articles for article (PubMed ID: 25897019)
1. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima.
Ben-Horin S; Yavzori M; Benhar I; Fudim E; Picard O; Ungar B; Lee S; Kim S; Eliakim R; Chowers Y
Gut; 2016 Jul; 65(7):1132-8. PubMed ID: 25897019
[TBL] [Abstract][Full Text] [Related]
2. Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition.
Goncalves J; Santos M; Acurcio R; Iria I; Gouveia L; Matos Brito P; Catarina Cunha-Santos A; Barbas A; Galvão J; Barbosa I; Aires da Silva F; Alcobia A; Cavaco M; Cardoso M; Delgado Alves J; Carey JJ; Dörner T; Eurico Fonseca J; Palmela C; Torres J; Lima Vieira C; Trabuco D; Fiorino G; Strik A; Yavzori M; Rosa I; Correia L; Magro F; D'Haens G; Ben-Horin S; Lakatos PL; Danese S
Aliment Pharmacol Ther; 2018 Sep; 48(5):507-522. PubMed ID: 29873091
[TBL] [Abstract][Full Text] [Related]
3. Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease.
Fiorino G; Ruiz-Argüello MB; Maguregui A; Nagore D; Correale C; Radice S; Gilardi D; Allocca M; Furfaro F; Martínez A; Danese S
Inflamm Bowel Dis; 2018 Feb; 24(3):601-606. PubMed ID: 29462398
[TBL] [Abstract][Full Text] [Related]
4. Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars.
Ruiz-Argüello MB; Maguregui A; Ruiz Del Agua A; Pascual-Salcedo D; Martínez-Feito A; Jurado T; Plasencia C; Balsa A; Llinares-Tello F; Rosas J; Torres N; Martínez A; Nagore D
Ann Rheum Dis; 2016 Sep; 75(9):1693-6. PubMed ID: 26965981
[TBL] [Abstract][Full Text] [Related]
5. Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical Samples.
Gils A; Van Stappen T; Dreesen E; Storme R; Vermeire S; Declerck PJ
Inflamm Bowel Dis; 2016 Apr; 22(4):969-75. PubMed ID: 26954707
[TBL] [Abstract][Full Text] [Related]
6. Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study.
Smits LJ; Derikx LA; de Jong DJ; Boshuizen RS; van Esch AA; Drenth JP; Hoentjen F
J Crohns Colitis; 2016 Nov; 10(11):1287-1293. PubMed ID: 27095751
[TBL] [Abstract][Full Text] [Related]
7. Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF-α biologicals and an Infliximab-biosimilar.
Buurman DJ; Blokzijl T; Festen EAM; Pham BT; Faber KN; Brouwer E; Dijkstra G
PLoS One; 2018; 13(12):e0208922. PubMed ID: 30533022
[TBL] [Abstract][Full Text] [Related]
8. Experience with Biosimilar Infliximab (Remsima®) in Norway.
Jahnsen J; Kaasen Jørgensen K
Dig Dis; 2017; 35(1-2):83-90. PubMed ID: 28147374
[TBL] [Abstract][Full Text] [Related]
9. Switching from Remicade® to Remsima® is well Tolerated and Feasible: A Prospective, Open-label Study.
Buer LC; Moum BA; Cvancarova M; Warren DJ; Medhus AW; Høivik ML
J Crohns Colitis; 2017 Mar; 11(3):297-304. PubMed ID: 27660339
[TBL] [Abstract][Full Text] [Related]
10. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
Ben-Horin S; Heap GA; Ahmad T; Kim H; Kwon T; Chowers Y
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():27-34. PubMed ID: 26395532
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of Patients With Inflammatory Bowel Diseases Switched From Maintenance Therapy With a Biosimilar to Remicade.
Ilias A; Szanto K; Gonczi L; Kurti Z; Golovics PA; Farkas K; Schafer E; Szepes Z; Szalay B; Vincze A; Szamosi T; Molnar T; Lakatos PL
Clin Gastroenterol Hepatol; 2019 Nov; 17(12):2506-2513.e2. PubMed ID: 30630103
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents.
Reinisch W; Jahnsen J; Schreiber S; Danese S; Panés J; Balsa A; Park W; Kim J; Lee JU; Yoo DH
BioDrugs; 2017 Jun; 31(3):223-237. PubMed ID: 28497221
[TBL] [Abstract][Full Text] [Related]
13. Drug Survival and Immunogenicity After Switching From Remicade to Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: Two-year Follow-up of a Prospective Observational Cohort Study.
Smits LJT; van Esch AAJ; Derikx LAAP; Boshuizen R; de Jong DJ; Drenth JPH; Hoentjen F
Inflamm Bowel Dis; 2019 Jan; 25(1):172-179. PubMed ID: 29947795
[TBL] [Abstract][Full Text] [Related]
14. Physicochemical characterization of Remsima.
Jung SK; Lee KH; Jeon JW; Lee JW; Kwon BO; Kim YJ; Bae JS; Kim DI; Lee SY; Chang SJ
MAbs; 2014; 6(5):1163-77. PubMed ID: 25517302
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Clinical Outcomes After Switching from Remicade
Smits LJT; Grelack A; Derikx LAAP; de Jong DJ; van Esch AAJ; Boshuizen RS; Drenth JPH; Hoentjen F
Dig Dis Sci; 2017 Nov; 62(11):3117-3122. PubMed ID: 28667429
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Point-of-Care and Classical Immunoassays for the Monitoring Infliximab and Antibodies Against Infliximab in IBD.
Nasser Y; Labetoulle R; Harzallah I; Berger AE; Roblin X; Paul S
Dig Dis Sci; 2018 Oct; 63(10):2714-2721. PubMed ID: 29948562
[TBL] [Abstract][Full Text] [Related]
17. Comparison of immunogenicity test methods used in clinical studies of infliximab and its biosimilar (CT-P13).
Kim JS; Kim SH; Kwon B; Hong S
Expert Rev Clin Immunol; 2015; 11 Suppl 1():S33-41. PubMed ID: 26395835
[TBL] [Abstract][Full Text] [Related]
18. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD.
Frederiksen MT; Ainsworth MA; Brynskov J; Thomsen OO; Bendtzen K; Steenholdt C
Inflamm Bowel Dis; 2014 Oct; 20(10):1714-21. PubMed ID: 25069030
[TBL] [Abstract][Full Text] [Related]
19. Performance of Remsima® Monitor Drug Level versus RIDASCREEN IFX Monitoring in therapeutic drug monitoring of infliximab in patients with inflammatory bowel disease: A study of diagnostic accuracy.
Song JH; Hong SN; Kim ER; Chang DK; Kim YH
Medicine (Baltimore); 2022 Sep; 101(38):e30683. PubMed ID: 36197194
[TBL] [Abstract][Full Text] [Related]
20. Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme.
Razanskaite V; Bettey M; Downey L; Wright J; Callaghan J; Rush M; Whiteoak S; Ker S; Perry K; Underhill C; Efrem E; Ahmed I; Cummings F
J Crohns Colitis; 2017 Jun; 11(6):690-696. PubMed ID: 28130330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
